Topical κ‐Opioid Receptor Agonist Asimadoline Improves Dermatitis in a Canine Model of Atopic Dermatitis

xlomafota13 shared this article with you from Inoreader Topical κ‐Opioid Receptor Agonist Asimadoline Improves Dermatitis in a Canine Model of Atopic Dermatitis Via Experimental Dermatology Abstract This prospective, 4-week, placebo-controlled, cross-over study aimed to investigate the efficacy of 1% topical κ-opioid agonist, asimadoline, in a model of canine atopic dermatitis (AD). Fourteen beagles were challenged with house dust mites every 3-4 days for a total of 9 challenges. Severity of dermatitis was assessed and pruritus was monitored using GoPro HERO cameras. Pruritus scoring was evaluated at 10 time periods; baseline, 4 hours post allergen challenge and the last day of the study on Day 28. Scoring was done blindly by personnel using BORIS software. A global subjective score was also given using a visual analogue scale (VAS). A 4-week washout period occurred and dogs were crossed-over, the study was repeated and the results were analyzed using combined data. Gel was applied once daily on inguinal area (0.6 ml/dog). ANOVA showed significant effect of time (p<0.0001) and group (p=0.0001) on dermatitis scores. Overall, no statistically significant effect on pruritus was found due to a crossing of scores on day 17. Overtime the placebo scores increased while the active ingredient showed decrease after first 3 weeks. It is concluded that this approach is promising in dogs with AD and longer studies with more frequent application may be beneficial. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.